Overview
NICE is unable to make a recommendation about the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy because no evidence submission was received from The Medicines Company.
Last reviewed: 22 July 2015
Next review: We will review this decision if the company decides to make a submission.